- AGING AND LIMITED Physical Activity, as Well As The Use of Novel Weight Loss Drugs Such As Wegovy and Zepbound, Often Lead to The Simultaneous Loss of Muscle Mass and Bone Density.
- Medications are Currently Available for Bone Loss, But Approved Treatments for Muscle Mass Loss Are Lacking.
- A New Study in Mice Shows That the Antibody Treatment Bimagrumab Can Simultaneously Prevent a Decline in Bone Density Along With Muscle Mass.
- These findings suggest that bmagrumab could be potentially used to allevioate bone and muscle loss ow to glp-1 drarugs or aging.
Studies Suggest That Weight Loss Induced by Glucagon-Like Peptide-1 (LPG-1) Drugs Can Also Caja Decline In
A New Study Published in the
These findings suggest that bmagrumab could potentially Help Preserve not only Mass, as shown by Previous Research, But Also Help Prevent Bone Loss In Individual Using Glp-1 Drugs For Weight Loss.
The Study’s Author, Frederik Duch Bromer, A Researcher AT Aarhus University, Denmark, Said, “Since the Rise of Incbtin Therapies Like Wegovy and Mounjaro, Scientists Have Been Searching For Ways To Counteract The Loss of Muscle and Bone Mass offers off . Our Research Shows That Bimagrumab Can Mitigate Even More Severe Muscle and Bone Loss Than Whatpically Occurs With Weight Loss Therapies. ”
“As Bimagrumab is now Being Repurposed To Help Preserve Lean Mass During Weight Loss, its ABILITY TO PROTECT BONE AS well is specially relief given The Large Number of People Using before Treatments,” Bromer Told Medical News Today.
How Bimagrumab Works
To Loss of Muscle Mass and A Decline in Bone Density Are Common Features of Aging That Offen Occur Together. Thess of Muscle Mass and Strength With Aging Is Referred To As Sarcopenia, WHENERAS THE DECREASE IN BONE MASS AND BONE MINERAL DENSITY IS REFERRED TO AS
While Medications Are Avilable For The Treatment of Osteoporosis, There Is A Lack of Approved Treatments for Muscle Loss. One of the categories of Drugs Currently under investigation for the treatment of muscle loss includes that inhibit the activation of the activin receiver or the signaling pathway activated by this receiver.
Inhibition of the Activin Signaling Pathway Leads to Increased Muscle Mass and Bone Formation and Enhanced Blood Cell Formation. The Antibody Bimagrumab is an Example of One Such Drug That Binds To The Activin Receivers To Inhibit The Activation of the Activin Signaling Pathway. Similar to other inhibitors of the activin signaling pathway, animal and clinical studies have shown that bmagrumab can increase Muscle mass and lean body mass.
The Use of LPG-1 receiver agonists is associated with
Bones and Muscles Not only cooperate with each other during the Movements, but muscles Also Release Small Proteins Called Mykines That Impact Bone Health. However, it is not know whather bmagrumab can also simultaneously improve bone Health Along with Increasing Muscle Mass.
In the present Study, Refectchers Examined Whether Bimagrumab Could Improve Bone Health and Increase Muscle Mass Simultaneously.
The Inhibitors of the Activin Signaling Pathway Can Also Lead to an Increase in Blood Cell Production and Potentially Increase The Risk of Blood Clots. HELE, IT IS SENENTIAL TO ASSES THE RISK OF BLOOD CLOTS DUE TO BIMAGRUMAB BEFORE IT CAN BE Considers For Preventing Muscle and Bone Loss.
2 WEEKLY INJECTIONS OVER 21 SEYS
In the present Study, The Researchers Asessed the Impact of Bimagrumab on Muscle and Bone Mass in Healthy and Immobilized Mice, with the latter service as a model of bone and muscle loss.
To simulate the simultaneous loss of muscle mass and bone density, The Researchers Inject a Group of Mice with Botulinum Toxin into the quadriceps and the gastrocnemius, The Major Muscles of the Hindlimb. The Botulinum toxin Causes Paralysis of the Hindlimb Muscles, resulting in immobilization of the animal, followed by muscle mass loss and a decline in bone density.
The Healthy and Immobilized Mice in the Bimagrumab Group Received Two Weekly Antibody Injection Over 21 Days, WHENEAS THOSE IN THE CONTROL GROUPS REVIVED AN INJECTION OF THE VEHICLE. After 21 Days, The Mice in All Groups Were Euthanized, and The Muscles and Bones in the Right Hindlimb were removed and evaluated.
The Researchers Found That Bimagrumab Increased Muscle Mass, The Size of Muscle Fibers, and Bone Mineral Density in the Hindlimb of Both Free-Moving and Immobilized Mice. Bimagrumab Also promoted new bone formation, including at the end of the thigh bone or femur, which is prone to fracture in Older individuals.
Is Bimagrumab Safe in Humans?
The Scientists observed that the increased in muscle mass and bone mineral density was Smaller in the immobilized mice, Likely Due to the potent action of botulinum toxin. Yet, these results demonstrate that bmagrumab could potentially Help increase Muscle mass and bone density in individual at Risk of sarcopenia and osteoporosis.
The Rebecchers Also examined the Impact of Bimagrumab on Blood Cell Formation at Two and Seven Days After the Injection of the Antibody. Bimagrumab Did not have an impact on Blood Cell Formation or Any Other Related Factors, Suggesting ITS Safety for Serving Muscle and Bone Mass In Patients Using Glp-1 Drugs.
However, More Research and Larger Clinical Trials Will Be Needed To Determine ITS Effectiveness and Safety.
“While Our Study Focused on A Model of Muscle and Bone Loss, It Did Not Specifically Examine Bone Loss Related to Obesity. Since weight loss drarugs
